Spyre Therapeutics, Inc. (SYRE)
Nasdaq: SYRE · Pharmaceutical Preparations · Waltham, MA · filing with the SEC since 2015
Who owns Spyre Therapeutics, Inc.
As filed with the SECHolders of 5% or more
3
Harwin Peter Evan holds 9.99% of Common Stock, $0.0001 par value, as its SCHEDULE 13D/A filed Oct 9, 2026 says.
Directors and officers
13
report now, of 49 people on the record since 2016. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
Harwin Peter Evan
SCHEDULE 13D/A · filed Oct 9, 2026 · Common Stock, $0.0001 par value · 9.99% in Jun 23, 2026
Blackrock, Inc.
SCHEDULE 13G/A · filed Jul 16, 2025 · Common Stock
Paradigm BioCapital Advisors LP
SCHEDULE 13G · filed Oct 1, 2026 · Common Stock, $0.0001 par value per share
Perceptive Advisors LLC
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, $0.0001 Par Value Per Share · reported falling below 5%, from 5% in Apr 22, 2026
RTW Investments, LP
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, $0.0001 par value · reported falling below 5%, from 6.2% in Feb 14, 2025
Venrock Healthcare Capital Partners III, L.P.
SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%
Tang Capital Management, LLC
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 5.3% in May 1, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%, from 5.08% in Jul 29, 2025
What SYRE reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Spyre Therapeutics, Inc.
A company bought · asset acquisition · owns, named in the 10-K filed Feb 19, 2026
Insider tradesForm 4
96sales
0purchases
93sales on a scheduled plan
7people selling
$443Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Oct 2, 2025 to Oct 2, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 2, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window7 of 57 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | director | 1 | $400M | 0 | 0 | $0 |
| Turtle Cameron | Chief Executive Officer | 40 | $11.4M | 40 | 0 | $0 |
| Burrows Scott L | Chief Financial Officer | 26 | $9.1M | 24 | 0 | $0 |
| Henderson Michael Thomas | director | 5 | $8.0M | 5 | 0 | $0 |
| Sloan Sheldon | Chief Medical Officer | 11 | $7.4M | 11 | 0 | $0 |
| King-Jones Heidy | See Remarks | 10 | $5.1M | 10 | 0 | $0 |
| Albers Jeffrey W. | director | 3 | $2.4M | 3 | 0 | $0 |